Canada Markets close in 3 hrs 13 mins

PsyBio Therapeutics Corp. (PSYBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1715-0.0023 (-1.33%)
As of 11:55AM EST. Market open.

PsyBio Therapeutics Corp.

4400 West Sample Road
Suite 138
Coconut Creek, FL 33073
United States
513 449 9585
https://www.psybiolife.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Evan M. LevineCo-Founder, CEO & ChairmanN/AN/A1966
Mr. Noah Isidore DavisCFO, Sec. & DirectorN/AN/A1983
Mr. Ross CarmelChief Legal Officer & DirectorN/AN/AN/A
Dr. Michael Spigarelli M.B.A., M.B.E., M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Mr. Andrew JonesInventor & Chairman of Scientific Advisory BoardN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PsyBio Therapeutics Corp., a biotechnology company, develops formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health and other disorders in the United States. It also engages in the research and development of naturally occurring tryptamines in varieties of magic mushrooms, dimethyltryptamine which have therapeutics properties. The company was incorporated in 2020 and is headquartered in Coconut Creek, Florida.

Corporate Governance

PsyBio Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.